Table 3.
Crude and adjusted HRs of lung, breast, prostate, and colorectal cancers associated with telmisartan use compared with other ARBs
| Events | Person-years | Rate per 1,000/year (95% CI) | Crude HR | Adjusted HR (95% CI)a | |
|---|---|---|---|---|---|
| Lung cancer | |||||
| Other ARBs, n (%) | 264 | 228,355 | 1.2 (1.0–1.3) | 1.00 | 1.00 (Reference) |
| Telmisartan, n (%) | 16 | 15,684 | 1.0 (0.6–1.7) | 0.87 | 0.91 (0.55–1.51) |
| Breast cancer | |||||
| Other ARBs, n (%) | 385 | 114,388 | 3.4 (3.1–3.7) | 1.00 | 1.00 (Reference) |
| Telmisartan, n (%) | 34 | 7,829 | 4.3 (3.1–6.1) | 1.29 | 1.28 (0.90–1.82) |
| Prostate cancer | |||||
| Other ARBs, n (%) | 459 | 113,967 | 4.0 (3.7–4.4) | 1.00 | 1.00 (Reference) |
| Telmisartan, n (%) | 26 | 7,855 | 3.3 (2.3–4.9) | 0.82 | 0.79 (0.53–1.18) |
| Colorectal cancer | |||||
| Other ARBs, n (%) | 274 | 228,355 | 1.2 (1.1–1.4) | 1.00 | 1.00 (Reference) |
| Telmisartan, n (%) | 27 | 15,684 | 1.7 (1.2–2.5) | 1.41 | 1.41 (0.95–2.10) |
| Other cancers | |||||
| Other ARBs, n (%) | 2,330 | 228,355 | 10.2 (9.8–10.6) | 1.00 | 1.00 (Reference) |
| Telmisartan, n (%) | 132 | 15,684 | 8.4 (7.1–10.0) | 0.82 | 0.83 (0.70–0.99) |
Abbreviations: ARB, angiotensin receptor blocker; CI, confidence interval; HR, hazard ratio; PSA, prostate-specific antigen.
aAdjusted for the variables listed in Table 1. In addition, cholecystectomy, inflammatory bowel disease and history of polyps for colorectal cancer; benign prostatic hyperplasia, 5-alpha reductase inhibitors, and number of PSA tests for prostate cancer; oophorectomy, use of hormone replacement therapy, and prior use of oral contraceptives for breast cancer.